Barclays raised the firm’s price target on Elevance Health (ELV) to $522 from $512 and keeps an Overweight rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong Q1 2025 Results
- Elevance Health Q1 2025 Earnings Call Highlights
- Morning Movers: Danaher gains and Northrop Grumman sinks after earnings
- Elevance Health reports Q1 adjusted EPS $11.97, consensus $11.48
- Elevance Health backs FY25 adjusted EPS view of $34.15-$34.85, consensus $34.19